TGA resources
TGA guidance Summary of evidence for medicinal cannabis
- Medicinal cannabis products: Patient information
- Guidance for the use of medicinal cannabis in Australia: Patient information
- Guidance for the use of medicinal cannabis in Australia: Overview
- Guidance for the use of medicinal cannabis in the treatment of multiple sclerosis in Australia
- Guidance for the use of medicinal cannabis in the treatment of palliative care patients in Australia
- Guidance for the use of medicinal cannabis in the treatment of epilepsy in paediatric and young adult patients in Australia
- Guidance for the use of medicinal cannabis for the prevention or management of nausea and vomiting in Australia
- Guidance for the use of medicinal cannabis in the treatment of chronic non-cancer pain in Australia
RACGP Position Statement
RACGP – Medicinal use of cannabis products
| 1 RACGP Position Statement: Medicinal use of cannabis products Much of the detail remains unclear. For example, the legislation does not specify which products will be covered under the amendment, and it does not specify which particular conditions or symptoms will be eligible for treatment with cannabis-based products. www.racgp.org.au |
Cannabinoid Research
Product selection
- The Compendium
- List of Manufacturers and suppliers of medicinal cannabis products
- The TGA’s list of products by active ingredient